PIK3CA
PIK3CA encodes the catalytic p110α subunit of class I phosphoinositide 3-kinase (PIK3CA), a central signaling enzyme in pathways that regulate cell growth, survival, metabolism, and proliferation.
PIK3CA encodes the catalytic p110α subunit of class I phosphoinositide 3-kinase (PIK3CA), a central signaling enzyme in pathways that regulate cell growth, survival, metabolism, and proliferation. As a protein target, PIK3CA is especially important in oncology because activating mutations can drive aberrant Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) signaling and contribute to tumor progression and therapy resistance.
In biomedical research, PIK3CA is frequently studied as a drug target for selective PIK3CA inhibition. This is particularly relevant in cancers such as cervical cancer and breast cancer, where mutant PIK3CA can create a dependency on PIK3CA signaling. Recent studies also place PIK3CA within broader pathway networks involving EGFR/SRC-mediated EMT, KRAS, mitogen-activated protein kinase 1 (MAPK1), PTGS2, and the PI3K/Akt signaling pathway, underscoring its role as a hub in oncogenic signaling.
Where the papers sit
15 papers from the last 6 months study PIK3CA directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 4 observational · 3 human data · 7 preclinical · 1 unclassified
Themes no clear themes
Those 15 do not share a common subject.
-
PIK3CA appears across diverse studies of cancer mutations, signaling, therapeutic response, and molecular profiling. Individual papers address immunogenicity, ferroptosis, PI3Kα inhibition, mutant-selective inhibitors, and unrelated clinical or analytical questions. The set also includes case reports, plant metabolomics, and assay development, with no shared disease or consistent treatment strategy. Its breadth provides no defensible direction beyond continued investigation of PIK3CA in varied biological and translational contexts.
Papers
The 15 papers from the last 6 months that study PIK3CA directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (15)
- Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients. PLoS biology · 5 Oct 2026 PMID 42832529
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. Oncotarget · 21 Jul 2026 PMID 42478852
- Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
- Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma. Journal for immunotherapy of cancer · 7 Jul 2026 PMID 42413983
- Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib. Biochemical and biophysical research communications · 24 Jun 2026 PMID 42341421
- TRERNA1-mediated acetylation represses ferroptosis of non-small cell lung cancer cells via the KAT6A/H3K23ac/TRIM24-PIK3CA pathway. Human cell · 24 Jun 2026 PMID 42340519
- Renal vein thrombosis as a reversible vascular renal complication of CLOVES syndrome: a case report. CEN case reports · 23 Jun 2026 PMID 42334730
- Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
- Comparative metabolomic profiling and potential bioactive marker discovery of three Clerodendrum species and their different plant parts. Fitoterapia · 3 Jun 2026 PMID 42235855
- (Phospho)proteomic Profiling Reveals Mutation-Specific Adaptive Signaling to PI3Kα Inhibition in PIK3CA Mutant Breast Epithelial Cells. Journal of proteome research · 28 May 2026 PMID 42204977
- Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell reports. Medicine · 22 May 2026 PMID 42173096
- Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
- Design, synthesis, and anti-colorectal cancer activity of quinoxalines with improved drug-like properties. Bioorganic chemistry · 12 May 2026 PMID 42119204
- Benzothiophene-based, orally active PIK3CA H1047R mutant-selective inhibitors for the treatment of HR+/HER2- breast cancer. European journal of medicinal chemistry · 23 Apr 2026 PMID 42024964
By study type
Observational studies and case reports (4)
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. Oncotarget · 21 Jul 2026 PMID 42478852
- Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
- Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma. Journal for immunotherapy of cancer · 7 Jul 2026 PMID 42413983
- Renal vein thrombosis as a reversible vascular renal complication of CLOVES syndrome: a case report. CEN case reports · 23 Jun 2026 PMID 42334730
Human data, design not indexed (3)
- Integrated multi-omics analysis reveals the molecular landscape and therapeutic strategies in Chinese cervical cancer patients. PLoS biology · 5 Oct 2026 PMID 42832529
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- Single-nucleotide variant profiling in liquid biopsy with RECO-Cas. Science advances · 22 May 2026 PMID 42172311
Preclinical: animal, cell and lab studies (7)
- Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib. Biochemical and biophysical research communications · 24 Jun 2026 PMID 42341421
- TRERNA1-mediated acetylation represses ferroptosis of non-small cell lung cancer cells via the KAT6A/H3K23ac/TRIM24-PIK3CA pathway. Human cell · 24 Jun 2026 PMID 42340519
- Comparative metabolomic profiling and potential bioactive marker discovery of three Clerodendrum species and their different plant parts. Fitoterapia · 3 Jun 2026 PMID 42235855
- (Phospho)proteomic Profiling Reveals Mutation-Specific Adaptive Signaling to PI3Kα Inhibition in PIK3CA Mutant Breast Epithelial Cells. Journal of proteome research · 28 May 2026 PMID 42204977
- Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression. Cell reports. Medicine · 22 May 2026 PMID 42173096
- Design, synthesis, and anti-colorectal cancer activity of quinoxalines with improved drug-like properties. Bioorganic chemistry · 12 May 2026 PMID 42119204
- Benzothiophene-based, orally active PIK3CA H1047R mutant-selective inhibitors for the treatment of HR+/HER2- breast cancer. European journal of medicinal chemistry · 23 Apr 2026 PMID 42024964
Unclassified: not yet indexed with MeSH (1)
- Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer. NPJ breast cancer · 17 Jun 2026 PMID 42310300
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.